ReviewFrontiers in immunology2026
From clinical remission to biological stability in psoriasis: an antigen-blood-tissue framework for relapse stratification.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relapse after treatment withdrawal remains a major challenge in psoriasis. Despite high rates of clinical clearance with modern systemic therapies, durable off-therapy control is uncommon, and recurrence often reappears at previously affected sites. Current models centered on resolved-skin inflammatory memory explain important aspects of local recall, but may not fully account for the heterogeneity of relapse timing, pattern and durability seen across patients. Here, we review psoriasis relapse through a clinically oriented multilevel framework that integrates three interacting dimensions: an antigenic dimension, blood-accessible relapse-associated signals and programs, and tissue permissiveness. Presentation-level antigen evidence raises the possibility that selected psoriatic phenotypes are associated with distinct upstream inflammatory programs, although direct links to relapse remain unproven. Circulating skin-homing memory populations, relapse-associated blood candidates and resident-derived mobile programs suggest, but do not establish, that relapse-relevant memory may remain accessible outside the skin during remission. At the tissue level, molecular scarring, epidermal tissue-resident memory T cells and stromal-epithelial support help explain why recurrence is preferentially re-executed in previously involved skin. We propose the Antigen-Blood-Tissue model as a falsifiable structure for interpreting relapse heterogeneity rather than a closed explanation of recurrence. Clinically, this framework suggests that visible clearance and biological stability should not be considered interchangeable. It also supports the view that remission may represent a biologically variable state, and that prospective studies aligned to treatment tapering or withdrawal will be needed to determine whether biological stability can eventually be defined beyond clinical remission and related prospectively to relapse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.